The New York City–based pharmaceutical company delivered strong financial results in 2021, with total revenue growing 9% year over year to $46.4 billion. Bristol-Myers Squibb enjoyed strong sales for drugs like Revlimid and Opdivo, used in the treatment of certain cancers; and Eliquis, an anticoagulant. Its product-development pipeline also looks healthy: In 2021, the company obtained more than 20 regulatory approvals for new medicines. 
Illustration by Moukkaa

Company Information

As of 2/1/2023
Country
U.S.
Headquarters
New York City
Industry
Pharmaceuticals
CEO
Giovanni Caforio
Company Type
Public
Ticker
BMY
Revenues ($M)
$46,738
Profits ($M)
$6,677
Market Value ($M)
$157,655
Employees
32,200
Figures are for the latest twelve months ended Sept. 30, 2022. Market value as of Jan. 20, 2023. Sources: Bloomberg; S&P Global.

Key Financials (Last Fiscal Year)

$ millions
% change
Revenues ($M)
$46,385
9.1%
Profits ($M)
$6,994
-
Assets ($M)
$109,314
-
Total Stockholder Equity ($M)
$35,946
-

Profit Ratios

Profit as % of Revenues
15.1%
Profits as % of Assets
6.4%
Profits as % of Stockholder Equity
19.5%

Earnings Per Share (Last Fiscal Year)

Earnings Per Share ($)
312
EPS % Change (from 2020)
-
EPS % Change (5 year annual rate)
3.3%
EPS % Change (10 year annual rate)
3.7%

Total Return

Total Return to Investors (2021)
3.7%
Total Return to Investors (5 year, annualized)
4.4%
Total Return to Investors (10 year, annualized)
9.1%

Bristol-Myers Squibb Rank History

Historical Data

YearRevenues ($M)Profits ($M)Assets ($M)Total Stockholder Equity ($M)
2021$42,51862.6%$-9,015-362.1%$118,481$37,822
2020$26,14515.9%$3,439-30.1%$129,944$51,598
2019$22,5618.6%$4,920388.6%$34,986$14,031
2018$20,7766.9%$1,007-77.4%$33,551$11,741
2017$19,42717.3%$4,457184.8%$33,707$16,177
SHOW MORE
FortuneDataStore ad
Lists ranking Bristol-Myers Squibb
RANK100000
World's Most Admired Companies - 2023The 25th Fortune World’s Most Admired Companies li...READ MORE
RANK82
Fortune 500 - 2022This year’s Fortune 500 marks the 68th running of ...READ MORE
RANK301
Global 500 - 2022Aggregate sales hit $37.8 trillion last year—an in...READ MORE
RANK23
Fortune Modern Board 25 - 2022Fortune collaborated with the Diligent Institute t...READ MORE